BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join
back to Directory

OrphAI Therapeutics (formerly AI Therapeutics)

OrphAI Therapeutics (formerly AI Therapeutics) logo

Website
https://www.orphai-therapeutics.com/
Founded
2013
Patents
25
Clinical Trials
2
Publications
16

Technologies

AI Companies (Drug Discovery)

We are an AI-driven company with a unique ability to match drugs to indications and prosecute through clinical development. AI Therapeutics’ revolutionary approach to drug discovery and development has advanced three drugs into clinical trials.

AI Therapeutics was founded in 2013 as LAM Therapeutics with a mission to advance the clinical development of new therapies to treat Lymphangioleiomyomatosis (LAM) and other diseases. In 2018 we changed our name to AI Therapeutics. Working with a dedicated team of scientific, clinical, and drug development experts, AI Therapeutics is pioneering deep learning-based AI to outsmart cancer and rare diseases.

#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

 

R&D Platform

Advanced deep learning to predict drugs for any indication.
Guardian Angel™ Algorithm

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.